Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistanceOncogene.  38:6159-6171. 2019
2019 A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening.Cells.  8. 2019
2019 A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain TumorCancer Cell.  36:51-67.e7. 2019
2019 Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain TumorsWorld Neurosurgery.  122:e1592-e1598. 2019
2019 Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesisJournal of Neuro-Oncology.  141:289-301. 2019
2019 Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of miceCancer Gene Therapy2019
2018 Combinatorial drug testing in 3D microtumors derived from GBM patient-derived xenografts reveals cytotoxic synergy in pharmacokinomics-informed pathway interactionsScientific Reports.  8. 2018
2018 Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 ExpressionScientific Reports.  8. 2018
2018 BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated DegradationCancer Cell.  33:1004-1016.e5. 2018
2018 Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memoryTranslational Oncology.  11:86-93. 2018
2017 Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.JCI insight.  2. 2017
2017 Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002Molecular Therapy - Oncolytics.  7:27-36. 2017
2017 KLF6 depletion promotes NF-κB signaling in glioblastomaOncogene.  36:3562-3575. 2017
2017 Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell.  31:737-754.e6. 2017
2017 Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human PrimatesMolecular Therapy - Oncolytics.  5:1-10. 2017
2017 Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain TumorsHuman Gene Therapy Clinical Development.  28:7-16. 2017
2017 Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.Human Gene Therapy Clinical Development2017
2017 Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastomaJournal of Neuro-Oncology.  131:449-458. 2017
2017 Checkpoint proteins in pediatric brain and extracranial solid tumors: Opportunities for immunotherapyClinical Cancer Research.  23:342-350. 2017
2017 Combination strategies enhance oncolytic virotherapyOncotarget.  8:34020-34021. 2017
2017 Modeling Physiologic Microenvironments in Three-Dimensional Microtumors Maintains Brain Tumor Initiating Cells.Journal of cancer stem cell research.  5. 2017
2016 Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid TumorsCancer Cell.  30:891-908. 2016
2016 IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in miceJournal of Ovarian Research.  9:70. 2016
2016 IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in miceJournal of Ovarian Research.  9:1-11. 2016
2016 Effect of repeat dosing of engineered oncolytic herpes simplex virus on preclinical models of rhabdomyosarcomaTranslational Oncology.  9:419-430. 2016
2016 Generation of microtumors using 3D human biogel culture system and patient-derived glioblastoma cells for kinomic profiling and drug response testingJournal of Visualized Experiments.  2016. 2016
2016 Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or GliosarcomaHuman Gene Therapy Clinical Development.  27:69-78. 2016
2016 Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex virusesNeuro-Oncology.  18:227-235. 2016
2016 Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade NeuroblastomaJournal of Immunology Research.  2016. 2016
2016 Tamoxifen induces cytotoxic autophagy in glioblastomaJournal of Neuropathology and Experimental Neurology.  75:946-954. 2016
2015 A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic AgentsPLoS ONE.  10. 2015
2015 Synergistic antivascular and antitumor efficacy with combined cediranib and SC6889 in intracranial mouse gliomaPLoS ONE.  10. 2015
2015 Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CWBritish Journal of Neurosurgery.  29:850-858. 2015
2015 Patient-Derived Xenografts as a Model System for Radiation ResearchSeminars in Radiation Oncology.  25:273-280. 2015
2015 Pediatric cancer gone viral. Part I: Strategies for utilizing oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15015. 2015
2015 Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15016. 2015
2015 ROCK inhibition facilitates in vitro expansion of glioblastoma stem-like cellsPLoS ONE.  10. 2015
2015 KINOMIC ALTERATIONS IN ATYPICAL MENINGIOMA.Medical research archives.  2015. 2015
2015 Dynamics of circulating γδ T cell activity in an immunocompetent mouse model of high-grade gliomaPLoS ONE.  10. 2015
2015 Erratum: [γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia (Gene Therapy) (2015) 22: 348-355]Gene Therapy.  22:356. 2015
2015 Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomasOncotarget.  6:4330-4344. 2015
2015 γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxiaGene Therapy.  22:348-355. 2015
2014 Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulationPLoS ONE.  9. 2014
2014 Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to Aotus Nonhuman PrimatesHuman Gene Therapy Clinical Development.  25:16-27. 2014
2014 Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates.Human Gene Therapy Clinical Development2014
2014 Oncolytic viral therapy: targeting cancer stem cells.Oncolytic Virotherapy.  2014:21-33. 2014
2014 Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsPLoS ONE.  9. 2014
2014 A phase 1 trial of oncolytic HSV-1, g207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responsesMolecular Therapy.  22:1048-1055. 2014
2014 Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell linesGene Therapy.  21:984-990. 2014
2014 Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitroJournal of Neuro-Oncology.  118:61-72. 2014
2014 Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolinesRadiotherapy and Oncology.  111:468-474. 2014
2014 The role of Src family kinases in growth and migration of glioma stem cellsInternational Journal of Oncology.  45:302-310. 2014
2013 Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapyFrontiers in Oncology.  3 FEB. 2013
2013 Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse gliomaNeuro-Oncology.  15:1673-1683. 2013
2013 Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of NeuroblastomaPLoS ONE.  8. 2013
2013 CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated Vδ1+ γδ T CellsPLoS ONE.  8. 2013
2013 Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma MultiformePLoS ONE.  8. 2013
2013 Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and ImmunotherapyPLoS ONE.  8. 2013
2013 CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSVMedical and Pediatric Oncology.  60:45-52. 2013
2012 Subgroup-specific structural variation across 1,000 medulloblastoma genomesNature.  487:49-56. 2012
2012 MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for gliomaClinical Cancer Research.  18:3030-3041. 2012
2012 Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12Journal of Virology.  86:5304-5313. 2012
2012 Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific mannerPLoS ONE.  7. 2012
2012 Hypoxia moderates γ134.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary culturesTranslational Oncology.  5:200-207. 2012
2012 Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases.International Journal of Breast Cancer.  2012:628697. 2012
2012 Targeting pediatric cancer stem cells with oncolytic virotherapy.Pediatric Research.  71:500-510. 2012
2011 Therapeutic potential of AZD1480 for the treatment of human glioblastomaMolecular Cancer Therapeutics.  10:2384-2393. 2011
2011 Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1Gene Therapy.  18:1098-1102. 2011
2011 Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS productionPLoS ONE.  6. 2011
2011 Downregulation of FIP200 induces apoptosis of glioblastoma cells and microvascular endothelial cells by enhancing Pyk2 activityPLoS ONE.  6. 2011
2011 The RNA-binding protein HuR promotes glioma growth and treatment resistanceCell Growth and Differentiation.  9:648-659. 2011
2011 Cancer stem cells and pediatric solid tumorsCancers.  3:298-318. 2011
2011 The role of DDX3 in regulating SnailBiochimica et Biophysica Acta (BBA) - Molecular Cell Research.  1813:438-447. 2011
2011 Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiformeJournal of Neuro-Oncology.  101:179-188. 2011
2010 Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chainJournal of Biological Chemistry.  285:39759-39767. 2010
2010 Cross-species genomics matches driver mutations and cell compartments to model ependymomaNature.  466:632-636. 2010
2010 A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastomaArchives of Neurology -Chigago-.  67:313-319. 2010
2009 CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental gliomaCancer Gene Therapy.  16:794-805. 2009
2009 Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastomaNeuro-Oncology.  11:357-367. 2009
2009 Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111Journal of Neuro-Oncology.  95:199-209. 2009
2009 A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.Journal of Clinical Oncology.  27:2023. 2009
2009 Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.Journal of Clinical Oncology.  27:2042. 2009
2009 Herpes simplex virus oncolytic therapy for pediatric malignanciesMolecular Therapy.  17:1125-1135. 2009
2009 The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog-Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog-Treated Cerebellar Neural PrecursorsCancer Research.  69:3249-3255. 2009
2009 Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastomaNature Genetics.  41:465-472. 2009
2009 High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRIMagnetic Resonance in Medicine.  61:615-625. 2009
2009 Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBMMolecular Therapy.  17:199-207. 2009
2008 In Reply to Dr. SpeerInternational Journal of Radiation Oncology - Biology - Physics.  72:1274. 2008
2008 CD133 is a marker of bioenergetic stress in human gliomaPLoS ONE.  3. 2008
2008 Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expressionClinical Cancer Research.  14:4694-4704. 2008
2008 Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5International Journal of Radiation Oncology - Biology - Physics.  71:507-516. 2008
2008 Erratum: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (Gene Therapy (2008) vol. 14 (1111-1119) 10.1038/sj.gt.3302965)Gene Therapy.  15:327. 2008
2008 Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cellsCancer Research.  68:674-682. 2008
2008 A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomasMolecular Therapy.  16:627-632. 2008
2007 Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic virusesGene Therapy.  14:1045-1054. 2007
2007 Gene delivery into malignant glioma by infectivity-enhanced adenovirus: In vivo versus in vitro modelsNeuro-Oncology.  9:280-290. 2007
2007 Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro modelGene Therapy.  14:523-532. 2007
2007 Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brainJournal of NeuroVirology.  13:118-129. 2007
2007 Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patientsJournal of Proteome Research.  6:559-570. 2007
2007 Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumorsCancer Gene Therapy.  14:45-56. 2007
2007 Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human gliomaGene Therapy.  14:1111-1119. 2007
2007 Pharmacologic manipulations of mitochondrial membrane potential (ΔΨm) selectively in glioma cellsJournal of Neuro-Oncology.  81:9-20. 2007
2006 Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM)Journal of Neuro-Oncology.  80:261-274. 2006
2006 Oncolytic HSV-1 for the treatment of brain tumoursHerpes -Cambridge-.  13:66-71. 2006
2006 Serial passage through human glioma xenografts selects for a Δγ134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumorsJournal of Virology.  80:7308-7315. 2006
2006 Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cellsJournal of Biological Chemistry.  281:19220-19232. 2006
2006 Ex vivo activation and expansion of γδ T cells for immunotherapy of glioblastoma.Journal of Clinical Oncology.  24:2553. 2006
2006 A novel technique to quantify glioma tumor invasion using serial microscopy sectionsJournal of Neuroscience Methods.  153:183-189. 2006
2006 Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidatesVaccine.  24:1644-1652. 2006
2006 Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenograftsClinical Cancer Research.  12:1292-1298. 2006
2006 Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cellsCancer Research.  66:2257-2263. 2006
2006 Divergent effects of oncostatin M on astroglioma cells: Influence on cell proliferation, invasion, and expression of matrix metalloproteinasesGlia.  53:191-200. 2006
2005 Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infectionsNeurosurgery.  57:1237-1242. 2005
2005 Glucose metabolism heterogeneity in human and mouse malignant glioma cell linesJournal of Neuro-Oncology.  74:123-133. 2005
2005 Inhibition of cystine uptake disrupts the growth of primary brain tumors.Journal of Neuroscience.  25:7101-7110. 2005
2005 Changes in intracellular Ca2+ and pH in response to thapsigargin in human glioblastoma cells and normal astrocytesAmerican Journal of Physiology - Cell Physiology.  289. 2005
2005 Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma modelNeuro-Oncology.  7:213-224. 2005
2005 Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cellsCancer Research.  65:5535-5543. 2005
2005 TRAIL death receptor therapy for malignant glioma.Journal of Clinical Oncology.  23:3187. 2005
2005 Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12Cancer Gene Therapy.  12:359-368. 2005
2005 Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapyHuman Gene Therapy.  16:339-347. 2005
2005 Glucose metabolism heterogeneity in malignant glioma: LDH-B, a potential marker for slow growing experimental gliomaJ. Neurooncol..  74:123-133. 2005
2005 Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing miceJournal of Neuro-Oncology.  71:113-119. 2005
2004 Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1American Journal of Physiology - Cell Physiology.  287. 2004
2004 Transcriptional targeting of adenovirally delivered tumor necrosis factor α by temozolomide in experimental glioblastomaCancer Research.  64:6381-6384. 2004
2003 Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomasJournal of Neuro-Oncology.  65:203-226. 2003
2003 Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cellsBiochemical and Biophysical Research Communications.  309:952-960. 2003
2003 Molecular cloning and characterization of human acid sensing ion channel (ASIC)2 gene promoterGene.  313:91-101. 2003
2003 Acid-sensing ion channels in malignant gliomasJournal of Biological Chemistry.  278:15023-15034. 2003
2003 Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug deliveryBioconjugate Chemistry.  14:302-310. 2003
2003 Measurement of the mass difference [Formula Presented] at CDF IIPhysical Review D, Particles and fields.  68. 2003
2002 Protein kinase C isoform antagonism controls BNaC2 (ASIC1) functionJournal of Biological Chemistry.  277:45734-45740. 2002
2002 Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiationMolecular Cancer Therapeutics.  1:1139-1145. 2002
2002 Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cellsMolecular Therapy.  6:190-198. 2002
2002 Human cytomegalovirus infection and expression in human malignant gliomaCancer Research.  62:3347-3350. 2002
2002 Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samplesCancer Research.  62:2699-2707. 2002
2002 Fas engagement increases expression of interleukin-6 in human glioma cellsJournal of Neuro-Oncology.  56:13-19. 2002
2002 The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatomaGene Therapy.  9:75-80. 2002
2002 Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomasCancer Research.  62:773-780. 2002
2002 Second-site mutation outside of the Us10-12 domain of δγ134.5 Herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase r and partially restores neurovirulenceJournal of Virology.  76:942-949. 2002
2002 The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatomaGene Therapy.  9:75-80. 2002
2001 RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse originsCancer Research.  61:8470-8479. 2001
2001 VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiformeMolecular Medicine.  7:598-608. 2001
2001 pH Alterations "Reset" Ca2+ Sensitivity of Brain Na+ Channel 2, a Degenerin/Epithelial Na+ Ion Channel, in Planar Lipid BilayersJournal of Biological Chemistry.  276:38755-38761. 2001
2001 Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: Possible functional consequencesArchives of Biochemistry and Biophysics.  394:167-172. 2001
2001 Differential gene expression profiling in human brain tumorsPhysiological Genomics.  2001:21-33. 2001
2001 Genetically engineered human herpes simplex virus in the treatment of brain tumoursHerpes -Cambridge-.  8:17-22. 2001
2001 Fas-induced expression of chemokines in human glioma cells: Involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinaseCancer Research.  61:3084-3091. 2001
2001 HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAsCancer Research.  61:2154-2161. 2001
2000 Expression of a restrictive receptor for interleukin 13 is associated with glial transformationJournal of Neuro-Oncology.  48:103-111. 2000
2000 Immunotherapy of a murine T cell lymphoma localized to the brainJournal of Neuro-Oncology.  47:1-10. 2000
2000 Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.Gene Therapy.  7:867-874. 2000
2000 Genetically engineered HSV in the treatment of glioma: A reviewReviews in Medical Virology.  10:17-30. 2000
2000 Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumorsProceedings of the National Academy of Sciences.  97:2208-2213. 2000
2000 Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trialGene Therapy.  7:867-874. 2000
2000 Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents.Journal of Neuro-Oncology.  46:135-144. 2000
2000 Targeted foreign gene expression in spinal cord neurons using poliovirus repliconsJournal of NeuroVirology.  6:95-105. 2000
1999 Malignant human gliomas express an amiloride-sensitive Na+ conductanceAmerican Journal of Physiology - Cell Physiology.  276. 1999
1999 Ionizing radiation improves survival in mice bearing intracranial high- grade gliomas injected with genetically modified herpes simplex virusClinical Cancer Research.  5:1517-1522. 1999
1999 Glioma migration can be blocked by nontoxic inhibitors of myosin IICancer Research.  59:2076-2082. 1999
1999 Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomasClinical Cancer Research.  5:985-990. 1999
1999 Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumorsCancer Research.  59:2055-2058. 1999
1999 Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylaseNucleosides and Nucleotides.  18:745-757. 1999
1999 Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme.International Journal of Oncology.  15:481-486. 1999
1998 Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transferCancer Research.  58:5738-5748. 1998
1998 Use of chlorotoxin for targeting of primary brain tumorsCancer Research.  58:4871-4879. 1998
1998 Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rateProceedings of the National Academy of Sciences.  95:8795-8800. 1998
1998 Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cellsBiochemical Pharmacology.  55:1673-1681. 1998
1998 Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effectsCancer Research.  58:1893-1900. 1998
1998 TPA-mediated regulation of osteopontin in human malignant glioma cellsAnticancer Research.  18:807-812. 1998
1998 TPA-mediated regulation of osteopontin in human malignant glioma cells.Anticancer Research.  18:807-812. 1998
1998 Expression of voltage-activated chloride currents in acute slices of human gliomasNeuroscience.  83:1161-1173. 1998
1998 Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsGene Therapy.  5:121-130. 1998
1997 In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylaseHuman Gene Therapy.  8:1637-1644. 1997
1997 Immunoreactivity of human MAb BT32/A6 with neuroepithelial tumorsJournal of Neuro-Oncology.  35:93-100. 1997
1997 Brain edema in meningiomas is associated with increased vascular endothelial growth factor expressionNeurosurgery.  40:1269-1277. 1997
1997 Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumorsCancer Research.  57:1502-1509. 1997
1997 In Vitro and In Vivo Gene Delivery Mediated By A Synthetic Polycationic Amino PolymerNature Biotechnology.  15:462-466. 1997
1996 Efficacy of genetically engineered HSV-1 viruses in treatment of human malignant gliomasFederation proceedings.  10. 1996
1996 The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumorsProceedings of the National Academy of Sciences.  93:11313-11318. 1996
1996 Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen geneGene Therapy.  3:567-580. 1996
1996 Human astrocytoma cells express a unique chloride currentNeuroReport.  7:1020-1024. 1996
1995 Human astrocytoma cells express a unique chloride currentNeuroReport.  7:343-347. 1995
1995 Loss of vascular endothelial growth factor in human alopecia hair follicles.Journal of Investigative Dermatology.  104:18S-20S. 1995
1995 Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant gliomaProceedings of the National Academy of Sciences.  92:1411-1415. 1995
1995 Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumorsJournal of Cell Science.  108:947-956. 1995
1995 Physiologic responses of REVC a continuous rabbit endothelial vascular cellJournal of Vascular Research.  32:31-40. 1995
1995 Up-regulation of urokinase and urokinase receptor genes in malignant astrocytomaAmerican Journal of Pathology.  146:1150-1160. 1995
1995 Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGFJournal of Neurosurgery.  82:864-873. 1995
1994 Monoclonal antibodies to glioma-derived growth factor(s)Hybridoma.  13:15-20. 1994
1994 Production of a bioactive high molecular weight transforming growth factor beta-like molecule by human malignant glioma cell linesGrowth Factors.  11:153-162. 1994
1993 Partial characterization of glioma-derived growth factor 2: A novel mitogenic activity from human cell line D-54 MGJournal of Neuro-Oncology.  17:99-109. 1993
1993 Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiologyCell regulation.  4:121-133. 1993
1992 Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium.Journal of Clinical Oncology.  10:452-458. 1992
1992 Interleukin-1β induction of tumor necrosis factor-alpha gene expression in human astroglioma cellsJournal of Neuroimmunology.  36:179-191. 1992
1992 Interleukin‐1β induction of TNF‐α gene expression: Involvement of protein kinase CJournal of Cellular Physiology.  152:264-273. 1992
1992 Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomasJournal of Clinical Oncology.  10:452-458. 1992
1990 Computerized tomography brain scan tumor volume determinations. Sensitivity as an objective criterion of response to therapyJournal of Neurosurgery.  72:872-878. 1990
1990 Tumor necrosis factor production and receptor expression by a human malignant glioma cell line, D54-MGJournal of Neuroimmunology.  30:1-13. 1990
1989 Systemic beta-interferon therapy for recurrent gliomas: a brief report.Journal of Neurosurgery.  71:639-641. 1989
1989 Growth factors derived from a human malignant glioma cell line, U-251MGJournal of Neuro-Oncology.  7:225-235. 1989
1989 A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in ratsJournal of Neurosurgery.  71:898-902. 1989
1989 Crosslinks between intramolecular pairs of ferritin subunits: Effects on both H and L subunits and on immunoreactivity of sheep spleen ferritinArchives of Biochemistry and Biophysics.  272:88-96. 1989
1989 Intracarotid cisplatin chemotherapy for recurrent gliomasJournal of Neurosurgery.  70:371-378. 1989
1989 Systemic beta-interferon therapy for recurrent gliomas: A brief reportJournal of Neurosurgery.  71:639-641. 1989
1988 Cell populations of tendon: A simplified method for isolation of synovial cells and internal fibroblasts: Confirmation of origin and biologic propertiesJournal of Orthopaedic Research.  6:83-94. 1988
1988 Systemic gamma-interferon therapy for recurrent gliomasJournal of Neurosurgery.  69:826-829. 1988
1988 Tendon synovial cells secrete fibronectin in vivo and in vitroJournal of Orthopaedic Research.  6:73-82. 1988
1987 Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomasJournal of Neuro-Oncology.  4:309-313. 1987
1987 Treatment of autochthonous rat brain tumors with steroid plus heparin: A brief reportJournal of Neuro-Oncology.  5:161-162. 1987
1987 Derivation of Monoclonal Antibodies to Human Somatomedin C/Insulin-Like Growth Factor IMethods in Enzymology.  146:207-216. 1987
1987 Differential retention of rhodamine 123 by avian sarcoma virus‐induced glioma and normal brain tissue of the rat in vivoCancer.  59:266-270. 1987
1987 Monoclonal antibody specific for the transverse tubular membrane of skeletal muscle activates the dihydropyridine-sensitive Ca2+ channel.Proceedings of the National Academy of Sciences.  84:5019-5023. 1987
1986 Brain tumors in man and animals: Report of a workshopEnvironmental Health Perspectives.  Vol. 68:155-173. 1986
1986 Immunobiology of human gliomasSeminars in Oncology.  13:94-109. 1986
1986 Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitroJournal of Neurosurgery.  64:918-923. 1986
1986 Monoclonal antibody specific for the T-tubule of skeletal muscleJournal of Histochemistry and Cytochemistry.  34:347-355. 1986
1985 Characterization of distinct tyrosine-specific protein kinases in B and T lymphocytesJournal of Biological Chemistry.  260:4351-4356. 1985
1985 Cellular immunolocalization of S100 protein within fixed tissue sections by monoclonal antibodiesArchives of Pathology and Laboratory Medicine.  109:117-122. 1985
1985 Characterization of monoclonal antibodies to Toxoplasma gondii tachyzoites by immunochemical techniquesFederation proceedings.  44. 1985
1985 Crosslinked protomers of apoferritin: Effect in the assembled molecule on immunoreactivity with monoclonal antibodies and electrophoretic mobilityFederation proceedings.  44. 1985
1985 Human interferon-gamma induces myeloid differentiation, LEU-1 and TAC expression and reduction of c-myc mRNA in HL-60 cellsFederation proceedings.  44. 1985
1985 Juxtadrenal schwannoma: Verification of the diagnosis by immunohistochemical and ultrastructural studiesJournal of Surgical Oncology.  30:259-268. 1985
1985 Response of glioma cells to interferon-gamma: increase in class II RNA, protein and mixed lymphocyte reaction-stimulating abilityEuropean Journal of Immunology.  15:809-814. 1985
1984 Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation.Proceedings of the National Academy of Sciences.  81:2347-2351. 1984
1984 Immunotherapy of patients with glioma: fact, fancy, and future.Progress in Experimental Tumor Research.  28:118-135. 1984
1984 Interferon-α and -γ promote myeloid differentiation of HL-60, a human acute promyelocytic leukemia cell lineJournal of biological response modifiers.  3:653-662. 1984
1984 Interferons (IFN) promote myeloid differentiation and augment cytotoxicity of a human promyelocytic leukemia cell line (HL-60)Federation proceedings.  43. 1984
1984 Macrophage-derived growth factor for fibroblasts and Interleukin-1 are distinct entities.Journal of Leukocyte Biology.  35:115-129. 1984
1984 Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylationProceedings of the National Academy of Sciences.  81:2347-2351. 1984
1984 Monoclonal antibodies against rabbit skeletal muscle 'triads'Federation proceedings.  43. 1984
1984 TLCK inhibits membrane tyrosine-specific protein kinase activaty from T but not B lymphocytesFederation proceedings.  43. 1984
1984 Tumoricidal activity of an acute promyelocytic leukemia cell line (HL-60) is augmented by human interferon alphaLeukemia Research.  8:801-811. 1984
1983 New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy.Clinical Neurosurgery.  31:456-469. 1983
1983 Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomasJournal of Neurosurgery.  59:208-216. 1983
1982 The golden age of mononuclear phagocytesImmunologic Research.  1:352-356. 1982
1982 Mitogenic activity elaborated by macrophage‐like cell lines acts as competence factor(s) for BALB/c 3T3 cellsJournal of Cellular Physiology.  110:93-100. 1982
1980 Comparison of responses to activating agents by mouse peritoneal macrophages and cells of the macrophage line RAW 264Journal of the Reticuloendothelial Society.  27:607-619. 1980
1980 Evidence for mononuclear phagocytes in solid neoplasms and appraisal of their nonspecific cytotoxic capabilities.Contemporary topics in immunobiology.  10:143-166. 1980
1980 Level of activation determines whether inflammatory peritoneal and intratumoral macrophages will promote or suppress in vitro development of cytolytic T lymphocyte activityJournal of the Reticuloendothelial Society.  27:535-545. 1980
1978 B‐tropic oncornavirus production by BALB/c methylcholanthrene‐induced sarcoma cellsInternational Journal of Cancer.  21:234-238. 1978
1978 Development and persistence of cytolytic T lymphocytes in regressing or progressing moloney sarcomasInternational Journal of Cancer.  21:94-99. 1978
1978 Lymphocyte mediated reactivity against malignant melanoma detected by a microcytotoxicity assay employing technetium‐99m labeled target cellsCancer.  41:2174-2182. 1978
1978 Resurgence of killing and in vivo protection mediated by lymphocytes cultured from lymph nodes draining moloney sarcomasBritish Journal of Cancer.  38:365-374. 1978
1977 Inflammatory cells in solid murine neoplasms. III. Cytotoxicity mediated in vitro by macrophages recovered from disaggregated regressing Moloney sarcomasJournal of Immunology.  118:1574-1579. 1977
1977 Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing moloney sarcomasJournal of Immunology.  119:564-570. 1977
1977 Nature, function and distribution of inflammatory cells in regressing and progressing Moloney sarcomasJournal of the Reticuloendothelial Society.  22:159-168. 1977
1977 Isolation of T-lymphocytes from disaggregated tumors, with high purity and good percentage recovery: brief communicationJNCI: Journal of the National Cancer Institute.  59:273-275. 1977
1976 Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of moloney sarcoma regression or progressionInternational Journal of Cancer.  18:331-338. 1976
1975 Receptor sites for antigen antibody complexes on cells derived from solid tumors: detection by means of antibody sensitized sheep erythrocytes labeled with technetium 99mJournal of Immunology.  114:950-957. 1975
1975 Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcomasInternational Journal of Cancer.  16:1022-1029. 1975
1974 Use of 99mTc as a radioisotopic label to study the migratory patterns of normal and neoplastic cellsJournal of Nuclear Medicine.  15:656-661. 1974
1974 Cyclic variations in cell-mediated immunity to skin allografts detected by the technetium-99m microcytotoxicity assayCellular Immunology.  13:472-483. 1974
1974 Lymphocyte mediated cytotoxicity against human melanoma detected by the technetium 99m microassayFederation proceedings.  33:3385. 1974
1974 The use of technetium-99m as a radioisotopic label to assess cell-mediated immunity in vitroCellular Immunology.  10:38-49. 1974
1973 Labeling of mammalian nucleated cells with (99m)TcJournal of Nuclear Medicine.  14:706-708. 1973
1973 A New Radioisotopic Microassay of Cell-Mediated Immunity Utilizing Technetium-99m Labeled Target CellsProceedings of the Society for Experimental Biology and Medicine.  142:378-382. 1973
1973 A Radioisotopic Microassay for Lymphotoxin Using Technetium-99 Labeled CellsProceedings of the Society for Experimental Biology and Medicine.  144:564-568. 1973
1973 Cyclic variations in allograft immunity detected by the technetium 99m microcytotoxicity assayFederation proceedings.  32:3698. 1973
1972 A new radioisotopic microcytotoxicity assay of cellular immunity utilizing technetium-99m.National Cancer Institute monograph.  35:39-41. 1972
1972 The stimulation and inhibition of nonimmune lymphocyte-mediated cytotoxicity in vitro.Journal of the Reticuloendothelial Society.  12:257-282. 1972
1972 A synergistic immunosuppressive effect of endotoxin and PHA-M on immunologic enhancement in mice.Zeitschrift fur Immunitatsforschung, experimentelle und klinische Immunologie.  143:31-42. 1972
1972 Dissection of the immunosuppressive effect of the Fc region of tumor-enhancing IgG.Zeitschrift fur Immunitatsforschung, experimentelle und klinische Immunologie.  143:43-58. 1972
1970 Immunologic enhancement induced by antibody fragments.Zeitschrift fur Immunitatsforschung, Allergie und klinische Immunologie.  140:259-267. 1970

Principal Investigator On

  • Private Grant  awarded by INCYSUS THERAPEUTICS INC. 2019 - 2020
  • Private Grant  awarded by VIVO BIOSCIENCES, INC. 2015 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • COMPLETED - Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas - Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Animal Models  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Brain Tumor Tissue Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Engineered HSV for the Treatment of Malignant Gliomas - Core B (Animal Model) - Experimental Glioma Animal Models  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Interrogation of Key Genomic Alterations in Glioblastoma Multiforme (GBM) for Identification of Molecular Pathways Critical to GBM Tumorigenesis and Progression  awarded by SOUTHERN RESEARCH INSTITUTE 2013 - 2015
  • American Cancer Society Post Doctoral Fellowship, Tumor Specific Targeted Oncolytic Virotherapy Using Genetically Engineered Adenovirus  awarded by American Cancer Society, Inc. 2012 - 2014
  • Private Grant  awarded by VIVO BIOSCIENCES, INC. 2013 - 2014
  • Interrogation of Key Genomic Alterations in Glioblastoma Multiforme (GBM) for Identification of Molecular Pathways Critical to GBM Tumorigenesis and Progression  awarded by SOUTHERN RESEARCH INSTITUTE 2010 - 2012
  • Molecular Therapeutics for Anaplastic Gliomas - Core A  awarded by National Cancer Institute/NIH/DHHS 2005 - 2011
  • Molecular Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011
  • Molecular Therapeutics for Anaplstic Gliomas - Core D  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011
  • Human GBM Xenograft Chemovulnerability and Genomic Profiling  awarded by Translational Genomics Research Institute (TGen) 2008 - 2011
  • Molecular Therapeutics for Anaplastic Gliomas - Career Development  awarded by National Cancer Institute/NIH/DHHS 2005 - 2008
  • Molecular Therapeutics for Anaplastic Gliomas - Pilot Projects  awarded by National Cancer Institute/NIH/DHHS 2005 - 2007
  • Molecular Therapeutics for Anaplastic Gliomas - Project 4 Consortium  awarded by National Cancer Institute/NIH/DHHS 2004 - 2007
  • Investigator On

  • Biological Comparisons Among Three Derivative Models of Glioma Patient Cancers Under Microenvironmental Stress  awarded by National Cancer Institute/NIH/DHHS 2018 - 2023
  • NN106 Cytochrome C Oxidase Activity In Newly Diagnosed Glioblastoma Multiforme (GBM)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2023
  • Biosynthetic Metabolic Pathway Regulation of Glioma Growth  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients with Recurrent Malignant Glioma  awarded by Gateway for Cancer Research (The) 2019 - 2022
  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by National Cancer Institute/NIH/DHHS 2018 - 2021
  • Boosting the Systemic and in Situ CD4+ T-Cell Responses to Malignant Glioma by Oncolytic HSV Virotherapy  awarded by DOD - Department of Defense 2018 - 2021
  • Dual PET/Fluorescence Imaging of Glioma with an MMP-14 Activabable Peptide Probe  awarded by DOD - Department of Defense 2018 - 2020
  • Canine Immuno Neurotherapeutics  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2020
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14)  awarded by Food & Drug Administration 2016 - 2020
  • Private Grant  awarded by CHAMPIONS ONCOLOGY 2018 - 2020
  • lmmunovirotherapy to Target Pediatric Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2018 - 2020
  • Expansion of G207 Trial  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2017 - 2020
  • Intraventricular Delivery of Engineered Oncolytic Herpes Simplex Virotherapy to Treat Localized and Metastatic Pediatric Brain Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2015 - 2019
  • MARCKS as a Novel Regulator of Glioblastoma Growth and Treatment Resistance  awarded by American Cancer Society, Inc. 2014 - 2019
  • Enhancement of lmmunovirotherapy with IDO Inhibition in Pediatric Medulloblastoma  awarded by HYUNDAI HOPE ON WHEELS 2016 - 2018
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Paracrine Signaling in Glioma: Bioenergetics Heterogeneity and Chemoresistance  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Cytochrome C Oxidase in Malignant Gliomas  awarded by National Cancer Institute/NIH/DHHS 2012 - 2018
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2016 - 2017
  • Engineered Oncolytic Herpes Simplex Virotherapy for Medulloblastomas  awarded by St. Baldrick's Foundation 2012 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Lumina III System for UAB Optical Imaging  awarded by NIH - OFFICE OF THE DIRECTOR 2016 - 2017
  • 3D-Microtumor_GBM Xenoline Proband Modeling of Kinome-Directed Therapy  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Role of CL-Channels and Transporters in Tumor-Associated Epilepsy  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2014 - 2016
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Evaluation pf Clinically-ready Oncolytic HSV in Pediatric Brain Tumors  awarded by HYUNDAI HOPE ON WHEELS 2013 - 2015
  • Engineered Herpes Simplex Virus for Treatment of Malignant Peripheral Nerve Sheath Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2011 - 2015
  • Amino Acid Transport and the Biology of Human Gliomas  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Core A. Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 3 - Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 4 - Lessons from the O.R.: Using Clinical Biologic Correlates to Inform HSV Trial Design  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2014 - 2015
  • Negative Impact of RNA Destabilizer Tristetraprolin on Glioma Growth  awarded by National Cancer Institute/NIH/DHHS 2009 - 2014
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2013 - 2014
  • Integrated Pharmacogenomic/Pharmacokinomic Approach to Optimize GBM Therapy  awarded by National Brain Tumor Society 2011 - 2013
  • Teaching Activities

    Education And Training

  • Doctor of Philosophy in Immunology, University of Mississippi 1971
  • Master of Science in Cytogenetics / Genetics / Clinical Genetics Technology / Technologist, University of Mississippi 1968
  • Bachelor of Arts in Biology, University of Mississippi 1965
  • Bachelor of Arts in Chemistry, University of Mississippi 1965
  • Full Name

  • George Gillespie